Randomized trial of a dry-powder, fibrin sealant in vascular procedures Abstract based on results presented at Society of Academic and Research Surgery meeting, Durham University, Durham, UK, January 7-8, 2015.

Nav Yash Gupta, Ian Chetter, Paul Hayes, Albert H. Albert, Gregory (Greg) Moneta, Surendra Shenoy, John P. Pribble, Linda A. Zuckerman

    Research output: Contribution to journalArticle

    5 Scopus citations


    Objective Topical hemostats are important adjuncts for stopping surgical bleeding. The safety and efficacy of Fibrocaps, a dry-powder, fibrin sealant containing human plasma-derived thrombin and fibrinogen, was evaluated in patients undergoing vascular surgical procedures. Methods In this single-blind trial (clinicaltrials.gov: NCT01527357), adult patients were randomized 2:1 to Fibrocaps plus gelatin sponge (Fibrocaps) vs gelatin sponge alone. Results are presented for the patient subset undergoing vascular procedures with suture hole bleeding. The primary efficacy endpoint compared time to hemostasis (TTH) over 5 minutes. Safety follow-up continued to day 29. Results A total of 175 patients were randomized and treated (Fibrocaps, 117; gelatin sponge, 58). Patients were predominately male (69%) and underwent arterial bypass (81%), arteriovenous graft formation (9%), or carotid endarterectomy (9%). Fibrocaps significantly reduced TTH compared with gelatin sponge (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.5-3.1; median TTH, 2 minutes; 95% CI, 1.5-2.5 vs 4 minutes; 95% CI, 3.0-5.0; P

    Original languageEnglish (US)
    Pages (from-to)1288-1295
    Number of pages8
    JournalJournal of Vascular Surgery
    Issue number5
    StatePublished - Nov 1 2015


    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Surgery

    Cite this